In Segment C, individuals will receive ABBV-744 and oral navitoclax. In Section D, individuals will obtain ABBV-744 and ruxolitinib. Participants will receive treatment until eventually disease progression or the contributors are unable to tolerate the study drugs. There may be greater treatment burden for individuals With this trial compared to https://franciscoshuix.newsbloger.com/32670081/5-simple-statements-about-abbv-744-clinical-trial-phase-1-results-explained